Atrial fibrillation bleeding risk and prediction while treated with direct oral anticoagulants in warfarin-naïve or warfarin-experienced patients.
Alexander C PerinoJun FanKrishna PundiSusan SchmittMitra KothariNatasha DinPaul A HeidenreichMintu P TurakhiaPublished in: Clinical cardiology (2022)
Patients' modified HAS-BLED score at the time of DOAC initiation, regardless of prior warfarin use, provided only modest discrimination for intracranial and nonintracranial bleeds. These data argue against maintaining DOAC eligible patients on warfarin therapy regardless of modified HAS-BLED score.
Keyphrases
- direct oral anticoagulants
- atrial fibrillation
- venous thromboembolism
- end stage renal disease
- newly diagnosed
- ejection fraction
- oral anticoagulants
- prognostic factors
- stem cells
- machine learning
- patient reported outcomes
- left atrial
- catheter ablation
- acute coronary syndrome
- mesenchymal stem cells
- smoking cessation
- patient reported